

North America Pharmaceuticals Market Size and Forecast (2021 - 2031)

<https://marketpublishers.com/r/N1F32A064B8BEN.html>

Date: March 2026

Pages: 268

Price: US\$ 3,450.00 (Single User License)

ID: N1F32A064B8BEN

Abstracts

The North American Pharmaceuticals Market is poised for significant growth, with projections indicating it will reach approximately USD 1,663.4 billion by 2031, up from USD 990.7 billion in 2024. This growth trajectory reflects a compound annual growth rate (CAGR) of 7.7% from 2025 to 2031, driven by various factors that are reshaping the landscape of the pharmaceutical industry in the region.

Market Overview

The North American pharmaceuticals market is primarily divided into three key countries: the United States, Canada, and Mexico. The growth of this market can be attributed to several critical factors, including the rising incidence of cancer, increased investments in research and development, and a surge in new product launches. Furthermore, strategic initiatives such as the introduction of innovative products, obtaining regulatory approvals, and forming collaborations and acquisitions are significantly contributing to the market's expansion.

A major driver of this market is the aging population in North America. As the demographic shifts towards an older population, the prevalence of chronic diseases and conditions that necessitate ongoing pharmaceutical treatment is expected to rise. According to the U.S. Census Bureau, by 2030, one in five Americans will be aged 65 or older, which will inevitably increase the demand for medications targeting age-related health issues.

Innovations and Regulatory Environment

The rapid advancements in biotechnology are also propelling the pharmaceuticals market forward. The emergence of biologic drugs, personalized medicine, and gene therapies has transformed the treatment landscape for various diseases, including cancer, rare genetic disorders, and autoimmune diseases. Notable innovations such as CAR-T cell therapies and monoclonal antibodies are gaining popularity and acceptance in the market.

The presence of robust regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and Health Canada, plays a crucial role in ensuring the safety, efficacy, and quality of pharmaceutical products. The stringent regulatory processes have led to a consistent influx of new drugs into the market, fostering innovation and consumer trust.

Moreover, the digital transformation of healthcare, characterized by the rise of telemedicine and digital therapeutics, is creating new opportunities for pharmaceutical companies. Collaborations with digital health providers can lead to integrated solutions for managing chronic diseases, personalized treatment plans, and remote patient monitoring, further enhancing the market's growth potential.

Market Segmentation

The North American pharmaceuticals market can be segmented based on various criteria:

By Molecule Type: The market is divided into Small Molecule and Biological/Biosimilar Products, with Small Molecule products holding the largest market share in 2024.

By Indication: The market is categorized into Metabolic Diseases, Cancer, Immunology, Respiratory Disorders, Cardiovascular Disorders, Neurology Disorders, Rare Diseases, and Others, with Cancer being the leading segment in 2024.

By Product: The market is split into Branded and Generic products, where Branded products dominate the market share.

By Type: The market is classified into Prescription and Over-the-Counter (OTC) Drugs, with Prescription drugs leading in market share.

By Distribution Channel: The market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies, with Hospital Pharmacies holding the largest share.

Future Outlook

Looking ahead, the North American pharmaceuticals market is expected to undergo significant transformations. Emerging regional powers are likely to redefine pharmaceutical dominance, shifting innovation and market focus beyond traditional centers. Supply chains are anticipated to diversify strategically to mitigate risks and

enhance agility in response to global uncertainties. Regulatory frameworks will evolve rapidly, incorporating digital tools and fostering cross-border collaborations to streamline drug approvals.

According to Oxford Economics, the global pharmaceuticals market, valued at USD 1.5 trillion in 2023, is on a steady growth trajectory, with expected expansions of 3% in 2024, 4% in 2025, and 3.6% in 2026. In the U.S., pharmaceutical growth is projected to moderate to 2.9% in 2024 and 2.5% in 2025, influenced by increased reshoring efforts for active pharmaceutical ingredient (API) production due to supply chain vulnerabilities. The rising demand for weight-loss drugs, anticipated to reach USD 80 billion by 2030, is also reshaping market priorities. The pharmaceutical industry is experiencing a fundamental transformation driven by shifting global power dynamics, supply chain diversification, and evolving regulations. The increasing demand for specialized medicines, coupled with intensified mergers and acquisitions, is reshaping the competitive landscape. Challenges such as regulatory complexities and cost pressures remain, necessitating greater agility and innovation within the industry.

In summary, the North American pharmaceuticals market is on a robust growth path, characterized by demographic shifts, technological advancements, and evolving healthcare needs. The future will be defined by the industry's ability to adapt to geopolitical, technological, and healthcare changes on a global scale.

Contents

1. INTRODUCTION

- 1.1 Report Guidance
- 1.2 Market Segmentation

2. EXECUTIVE SUMMARY

- 2.1 Key Insights

3. RESEARCH METHODOLOGY

- 3.1 Secondary Research
- 3.2 Primary Research
 - 3.2.1 Hypothesis formulation:
 - 3.2.2 Macroeconomic factor analysis:
 - 3.2.3 Developing base number:
 - 3.2.4 Data Triangulation:
 - 3.2.5 Country-level data:
- 3.3 Assumptions and Limitations

4. PHARMACEUTICAL MARKET LANDSCAPE

- 4.1 PEST Analysis
- 4.2 Regulatory Landscape
 - 4.2.1 North America
 - 4.2.1.1 United States
 - 4.2.1.2 Canada
 - 4.2.1.3 Mexico
- 4.3 List of Key Suppliers:
- 4.4 Average selling Price:
- 4.5 Sourcing Strategy:
- 4.6 Market Entry Barriers in the Global Pharmaceutical Market:
- 4.7 Top 10 Blockbuster Drugs Facing Patent Expiry in the Next 5 Years with Revenue Data and Market Impact:

5. NORTH AMERICA PHARMACEUTICAL MARKET – KEY MARKET DYNAMICS

5.1 North America Pharmaceutical Market – Key Market Dynamics

5.2 Market Drivers

5.2.1 Rising Global Disease Burden and Increasing Demand for Innovative Treatments

5.2.2 Expanding Global Access to Medicines and Growing Emerging Markets

5.3 Market Restraints

5.3.1 Regulatory Pressures and Market Shifts

5.4 Market Opportunities

5.4.1 Harnessing Innovation, AI, and Market Expansion

5.5 Future Trends

5.5.1 Regional Power Shifts, Supply Chain Diversification, and Regulatory Evolution

5.6 Impact of Drivers and Restraints:

6. PHARMACEUTICAL MARKET – NORTH AMERICA ANALYSIS

6.1 North America Pharmaceutical Market Revenue (US\$ Billion), 2021–2031

6.2 North America Pharmaceutical Market Forecast Analysis

7. NORTH AMERICA PHARMACEUTICAL MARKET ANALYSIS – BY MOLECULE TYPE

7.1 Small Molecule

7.1.1 Overview

7.1.2 Small Molecule: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

7.2 Biological and Biosimilar Products

7.2.1 Overview

7.2.2 Biological and Biosimilar Products: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

8. NORTH AMERICA PHARMACEUTICAL MARKET ANALYSIS – BY INDICATION

8.1 Metabolic Diseases

8.1.1 Overview

8.1.2 Metabolic Diseases: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

8.2 Cancer

8.2.1 Overview

8.2.2 Cancer: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

8.3 Immunology

8.3.1 Overview

8.3.2 Immunology: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

8.4 Respiratory Disorder

8.4.1 Overview

8.4.2 Respiratory Disorder: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

8.5 Cardiovascular Disorder

8.5.1 Overview

8.5.2 Cardiovascular Disorder: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

8.6 Neurology Disorder

8.6.1 Overview

8.6.2 Neurology Disorder: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

8.7 Rare Disease

8.7.1 Overview

8.7.2 Rare Disease: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

8.8 Others

8.8.1 Overview

8.8.2 Others: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

9. NORTH AMERICA PHARMACEUTICAL MARKET ANALYSIS – BY PRODUCT

9.1 Branded

9.1.1 Overview

9.1.2 Branded: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

9.2 Generic

9.2.1 Overview

9.2.2 Generic: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

10. NORTH AMERICA PHARMACEUTICAL MARKET ANALYSIS – BY TYPE

10.1 Prescription

10.1.1 Overview

10.1.2 Prescription: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

10.2 OTC Drugs

10.2.1 Overview

10.2.2 OTC Drugs: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

11. NORTH AMERICA PHARMACEUTICAL MARKET ANALYSIS – BY DISTRIBUTION CHANNEL

11.1 Hospital Pharmacies

11.1.1 Overview

11.1.2 Hospital Pharmacies: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

11.2 Retail Pharmacies

11.2.1 Overview

11.2.2 Retail Pharmacies: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

11.3 Online Pharmacies

11.3.1 Overview

11.3.2 Online Pharmacies: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

12. NORTH AMERICA PHARMACEUTICAL MARKET – COUNTRY ANALYSIS

12.1 North America

12.1.1 North America Pharmaceutical Market – Revenue and Forecast Analysis – by Country

12.1.1.1 North America Pharmaceutical Market – Revenue and Forecast Analysis – by Country

12.1.1.2 United States: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

12.1.1.2.1 United States: North America Pharmaceutical Market Share – by Molecule Type

12.1.1.2.2 United States: North America Pharmaceutical Market Share – by Indication

12.1.1.2.3 United States: North America Pharmaceutical Market Share – by Product

12.1.1.2.4 United States: North America Pharmaceutical Market Share – by Type

12.1.1.2.5 United States: North America Pharmaceutical Market Share – by Distribution Channel

12.1.1.3 Canada: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

12.1.1.3.1 Canada: North America Pharmaceutical Market Share – by Molecule Type

12.1.1.3.2 Canada: North America Pharmaceutical Market Share – by Indication

12.1.1.3.3 Canada: North America Pharmaceutical Market Share – by Product

12.1.1.3.4 Canada: North America Pharmaceutical Market Share – by Type

12.1.1.3.5 Canada: North America Pharmaceutical Market Share – by Distribution Channel

12.1.1.4 Mexico: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

12.1.1.4.1 Mexico: North America Pharmaceutical Market Share – by Molecule Type

12.1.1.4.2 Mexico: North America Pharmaceutical Market Share – by Indication

12.1.1.4.3 Mexico: North America Pharmaceutical Market Share – by Product

12.1.1.4.4 Mexico: North America Pharmaceutical Market Share – by Type

12.1.1.4.5 Mexico: North America Pharmaceutical Market Share – by Distribution Channel

13. COMPETITIVE LANDSCAPE

13.1 Company Market Share Analysis

14. INDUSTRY LANDSCAPE

14.1 Overview

14.2 Expansion

14.3 New Product Development

14.4 Merger and Acquisition

14.5 Partnerships

14.6 Other Business Strategies

15. COMPANY PROFILES

15.1 Johnson & Johnson

15.1.1 Key Facts

15.1.2 Business Description

15.1.3 Products and Services

- 15.1.4 Financial Overview
- 15.1.5 SWOT Analysis
- 15.1.6 Key Developments
- 15.2 Pfizer Inc
 - 15.2.1 Key Facts
 - 15.2.2 Business Description
 - 15.2.3 Products and Services
 - 15.2.4 Financial Overview
 - 15.2.5 SWOT Analysis
 - 15.2.6 Key Developments
- 15.3 Merck & Co Inc
 - 15.3.1 Key Facts
 - 15.3.2 Business Description
 - 15.3.3 Products and Services
 - 15.3.4 Financial Overview
 - 15.3.5 SWOT Analysis
 - 15.3.6 Key Developments
- 15.4 Eli Lilly and Co
 - 15.4.1 Key Facts
 - 15.4.2 Business Description
 - 15.4.3 Financial Overview
 - 15.4.4 SWOT Analysis
 - 15.4.5 Key Developments
- 15.5 Bristol-Myers Squibb Co
 - 15.5.1 Key Facts
 - 15.5.2 Business Description
 - 15.5.3 Products and Services
 - 15.5.4 Financial Overview
 - 15.5.5 SWOT Analysis
 - 15.5.6 Key Developments
- 15.6 ESTEVE
 - 15.6.1 Key Facts
 - 15.6.2 Business Description
 - 15.6.3 Products and Services
 - 15.6.4 Financial Overview
 - 15.6.5 SWOT Analysis
 - 15.6.6 Key Developments
- 15.7 UCB SA
 - 15.7.1 Key Facts

- 15.7.2 Business Description
- 15.7.3 Products and Services
- 15.7.4 Financial Overview
- 15.7.5 SWOT Analysis
- 15.7.6 Key Developments
- 15.8 Teva Pharmaceutical Industries Ltd
 - 15.8.1 Key Facts
 - 15.8.2 Business Description
 - 15.8.3 Products and Services
 - 15.8.4 Financial Overview
 - 15.8.5 SWOT Analysis
 - 15.8.6 Key Developments
- 15.9 Hikma Pharmaceuticals Plc
 - 15.9.1 Key Facts
 - 15.9.2 Business Description
 - 15.9.3 Products and Services
 - 15.9.4 Financial Overview
 - 15.9.5 SWOT Analysis
 - 15.9.6 Key Developments
- 15.10 Viatris Inc
 - 15.10.1 Key Facts
 - 15.10.2 Business Description
 - 15.10.3 Products and Services
 - 15.10.4 Financial Overview
 - 15.10.5 SWOT Analysis
 - 15.10.6 Key Developments
- 15.11 AstraZeneca Plc
 - 15.11.1 Key Facts
 - 15.11.2 Business Description
 - 15.11.3 Products and Services
 - 15.11.4 Financial Overview
 - 15.11.5 SWOT Analysis
 - 15.11.6 Key Developments
- 15.12 Sanofi SA
 - 15.12.1 Key Facts
 - 15.12.2 Business Description
 - 15.12.3 Products and Services
 - 15.12.4 Financial Overview
 - 15.12.5 SWOT Analysis

- 15.12.6 Key Developments
- 15.13 GSK Plc
 - 15.13.1 Key Facts
 - 15.13.2 Business Description
 - 15.13.3 Products and Services
 - 15.13.4 Financial Overview
 - 15.13.5 SWOT Analysis
 - 15.13.6 Key Developments
- 15.14 F. Hoffmann-La Roche Ltd
 - 15.14.1 Key Facts
 - 15.14.2 Business Description
 - 15.14.3 Products and Services
 - 15.14.4 Financial Overview
 - 15.14.5 SWOT Analysis
 - 15.14.6 Key Developments
- 15.15 Novartis AG
 - 15.15.1 Key Facts
 - 15.15.2 Business Description
 - 15.15.3 Products and Services
 - 15.15.4 Financial Overview
 - 15.15.5 SWOT Analysis
 - 15.15.6 Key Developments
- 15.16 AbbVie Inc
 - 15.16.1 Key Facts
 - 15.16.2 Business Description
 - 15.16.3 Products and Services
 - 15.16.4 Financial Overview
 - 15.16.5 SWOT Analysis
 - 15.16.6 Key Developments

16. APPENDIX

- 16.1 Glossary of Terms
- 16.2 About The Insight Partners

List Of Tables

LIST OF TABLES

Table 1. North America Pharmaceutical Market Segmentation

Table 2. North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Table 3. North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion) – by Molecule Type

Table 4. Table: Top-Selling Drugs in 2021

Table 5. North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion) – by Indication

Table 6. North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion) – by Product

Table 7. Key brands facing patent expirations

Table 8. North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion) – by Type

Table 9. North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion) – by Distribution Channel

Table 10. North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion) – by Country

Table 11. United States: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Molecule Type

Table 12. United States: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Indication

Table 13. United States: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Product

Table 14. United States: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Type

Table 15. United States: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Distribution Channel

Table 16. Canada: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Molecule Type

Table 17. Canada: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Indication

Table 18. Canada: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Product

Table 19. Canada: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Type

Table 20. Canada: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Distribution Channel

Table 21. Mexico: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Molecule Type

Table 22. Mexico: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Indication

Table 23. Mexico: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Product

Table 24. Mexico: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Type

Table 25. Mexico: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Distribution Channel

Table 26. Company Market Share Analysis

Table 27. Glossary of Terms, Pharmaceutical Market

List Of Figures

LIST OF FIGURES

Figure 1. North America Pharmaceutical Market Segmentation – Country

Figure 2. PEST Analysis

Figure 3. Impact Analysis of Drivers and Restraints

Figure 4. North America Pharmaceutical Market Revenue (US\$ Billion), 2021–2031

Figure 5. North America Pharmaceutical Market Share (%) – by Molecule Type (2024 and 2031)

Figure 6. Small Molecule: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 7. Biological and Biosimilar Products: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 8. North America Pharmaceutical Market Share (%) – by Indication (2024 and 2031)

Figure 9. Metabolic Diseases: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 10. Cancer: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 11. Immunology: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 12. Respiratory Disorder: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 13. Cardiovascular Disorder: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 14. Neurology Disorder: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 15. Rare Disease: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 16. Others: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 17. North America Pharmaceutical Market Share (%) – by Product (2024 and 2031)

Figure 18. Branded: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 19. Generic: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 20. North America Pharmaceutical Market Share (%) – by Type (2024 and 2031)

Figure 21. Prescription: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 22. OTC Drugs: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 23. North America Pharmaceutical Market Share (%) – by Distribution Channel (2024 and 2031)

Figure 24. Hospital Pharmacies: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 25. Retail Pharmacies: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 26. Online Pharmacies: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 27. North America Pharmaceutical Market Breakdown, by Key Countries, 2024 and 2031 (%)

Figure 28. United States: North America Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US\$ Billion)

Figure 29. Canada: North America Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US\$ Billion)

Figure 30. Mexico: North America Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US\$ Billion)

I would like to order

Product name: North America Pharmaceuticals Market Size and Forecast (2021 - 2031)

Product link: <https://marketpublishers.com/r/N1F32A064B8BEN.html>

Price: US\$ 3,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N1F32A064B8BEN.html>